According to a recently published report, the Global Ophthalmic Drugs Market is expected to grow at the CAGR of 7% during 2015-2022 and it is estimated to be $XX billion by 2022. The global ophthalmic drugs market is segmented on the basis of type, therapeutics, end user applications and geography. The report on global ophthalmic drugs market forecast 2015-2022 provides detailed overview and predictive analysis of the market.
The market is driven by various factors which include increase prevalence of eye related disorders such as glaucoma and cataract aging population, regulatory approvals to new drugs and devices, new technologies such as focus on combining drugs and device therapies and increasing economic factors such as rise in disposable income and health expenditure in emerging countries such as India and China. The market is expected to grow at good growth rate due to growing awareness especially in the emerging and underdeveloped countries. However, factors such as expiration of patents, drying pipelines and major slowdowns in economies may hamper the market growth.
The popular drugs include Lucentis, Eylea, Avastin, Restasis, Lumigan and Ganfort, Xalatan/Xalacom, Pataday and other. The drugs include drugs for glaucoma, retinal disorder, dry eye, allergic conjunctivitis, inflammation and conjunctivitis. The end users include hospitals, eye clinics, diagnostic centres and patients.
Full report available global ophthalmic drugs market forecast 2015-2022 report at http://www.briskinsights.com/report/global-ophthalmic-drugs-market-forecast-2015-2022
The major geographies include North America, Europe, Asia-Pacific and rest of the world. North America is the largest market followed by Europe and Asia pacific. The North American market is driven high awareness, availability of drugs due to presence of major players. Better regulatory policies have led to increased trust in the drugs. Asia Pacific market to have high growth rate driven by strong markets in China and India. Market includes top players such as Abbot Laboratories, ltd, Allergan Inc, Roche, Pfizer, Novartis, Bayer, Senju, Johnson and Johnson and Santen.
SCOPE OF THE REPORT
1. Global ophthalmic drugs market By type 2012 – 2022 ($ BILLION)
1.1. Global Prescription ophthalmic drugs market 2012 – 2022 ($ BILLION)
1.2. Global OTC (over the counter drugs) ophthalmic drugs market 2012 – 2022 ($ BILLION)
2. Global ophthalmic drugs market by therapeutics 2012 – 2022 ($ BILLION)
2.1. Global Glaucoma ophthalmic drugs market 2012 – 2022 ($ BILLION)
2.2. Global retinal disorder ophthalmic drugs market 2012 – 2022 ($ BILLION)
2.3. Global Dry eye ophthalmic drugs market 2012 – 2022 ($ BILLION)
2.4. Global Allergic conjunctivitis ophthalmic drugs market 2012 – 2022 ($ BILLION)
3. Global ophthalmic drugs market by end user 2012 – 2022 ($ BILLION)
3.1. Global Hospitals ophthalmic drugs market 2012 – 2022 ($ BILLION)
3.2. Global Eye clinics ophthalmic drugs market 2012 – 2022 ($ BILLION)
3.3. Global Diagnostic centers ophthalmic drugs market 2012 – 2022 ($ BILLION)
3.4. Global Patients ophthalmic drugs market 2012 – 2022 ($ BILLION)
4. Global ophthalmic drugs market regional outlook 2012-2022 ($ billion)
4.1. North America
4.3. Asia Pacific
4.4. Middle East & Africa
4.5. Central & South America
5. Competitive Landscape
5.1. Abbot Laboratories
5.2. Allergan Inc
5.3. Johnson and Johnson
5.10. Pfizer Inc
5.11. Roche holding AG
5.12. Santen pharmaceutical co. ltd
5.13. Merck & Co.
5.14. Novagali Pharma S.A.
5.15. Novartis AG
5.16. Cipla Pharmaceuticals
5.17. Sun Pharmaceuticals
5.19. Eye Gate Pharmaceuticals
Release ID: 893